EGCG 300 mg
Idiopathic Pulmonary Fibrosis
Clinical trials
2
Developer
Hal Chapman
Overview
EGCG 300 mg is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 2 tracked IPF clinical trials.
EGCG 300 mg clinical trials
Explore related
Medical disclaimer. This page summarizes research about EGCG 300 mg for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.